IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion

Clinical and Experimental Immunology

Volumn 135, Issue 2, 2004, Pages 322-329

  Knutson, K L ^a   Disis, M L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; IL 12; Peptide; T lymphocyte; Tumour antigen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN SPECIFICITY; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELL DIVISION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; LYMPHOCYTE SUBSETS; RECEPTOR, ERBB-2; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0842308742     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02360.x     Document Type: Article

References (30)

1. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188:2199-204.
2. Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 2000; 20:17-56.
3. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188:2357-68.
4. Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Importance of CD4(+) T helper cell responses in tumor immunity. Immunol Lett 2000; 74:75-9.
5. Knutson KL, Disis ML. Expansion of HER-2/neu specific T cells ex vivo following immunization with a HER-2/neu peptide-based vaccine. Clin Breast Ca 2001; 2:73-9.
6. Pawelec G, Schneider EM, Wernet P. Acquisition of suppressive activity and natural killer-like cytotoxicity by human alloproliferative 'helper' T cell clones. J Immunol 1986; 136:402-11.
7. Shortman K, Wilson A, Scollay R. Loss of specificity in cytolytic T lymphocyte clones obtained by limit dilution culture of Ly-2+ T cells. J Immunol 1984; 132:584-93.
8. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-27.
9. Lee K, Overwijk WW, O'Toole M, Swiniarski H, Restifo NP, Dorner AJ, Wolf SF, Sturmhoefel K. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. J Interferon Cytokine Res 2000; 20:589-96.
10. McFarland EJ, Harding PA, MaWhinney S, Schooley RT, Kuritzkes DR. In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children. 1998; 161:513-9.
11. Tuttle TM, Anderson BW, Thompson WE et al. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 1998; 4:2015-24.
12. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the her-2/neu protein after active immunization with HER-2/neu Peptide-based vaccines. J Clin Oncol 2002; 20:2624-32.
13. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytotoxic T cells specific for peptides derived from the HER-2/neu proto-oncogene protein. Ca Res 1994; 54:1071-6.
14. Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum Immunol 2002; 63:547-57.
15. Disis ML, Grabstein KH, Sleath PR, Ma C. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5:1289-97.
16. Cheever MA, Chen W. Therapy with cultured T cells: principles revisited. Immunol Rev 1997; 157:177-94.
17. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
18. Dudley ME, Wunderlich JR, Yang JC et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25:243-51.
19. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44.
20. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4.
21. Hu HM, Winter H, Urba WJ, Fox BA. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. Jimmunol 2000; 165:4246-53.
22. Reilly RT, Gottlieb MB, Ercolini AM et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000; 60:3569-76.
23. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge. CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000; 164:562-5.
24. Winter H, Hu HM, Poehlein CH et al. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology 2003; 108:409-19.
25. Pilon SA, Kelly C, Wei WZ. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 2003; 170:1202-8.
26. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107:477-84.
27. Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Storkus WJ. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. 1999; 162:3070-8.
28. Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 2003; 9:76-83.
29. Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999; 5:9-16.
30. Park JW, Gruys ME, McCormick K et al. Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2). J Immunol 2001; 166:3763-70.